Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may provide a promising development for obesity treatment. Initial patient trials have shown impressive reductions in abdominal tissue, conceivably exceeding existing obesity medications . Despite this, additional study is n